Fennec Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Fennec Pharmaceuticals de 63.7% y 27.9% respectivamente, mientras que el BPA crecerá en un 63.6% al año.

Información clave

63.7%

Tasa de crecimiento de los beneficios

63.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.7%
Tasa de crecimiento de los ingresos	27.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	18 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09

Recent updates

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Oct 04

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:FENC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	99	41	37	37	3
12/31/2025	61	4	14	14	5
12/31/2024	48	-2	14	13	4
9/30/2024	49	-1	24	24	N/A
6/30/2024	49	3	23	23	N/A
3/31/2024	45	3	27	27	N/A
12/31/2023	21	-16	-17	-17	N/A
9/30/2023	13	-20	-19	-19	N/A
6/30/2023	7	-26	-21	-21	N/A
3/31/2023	3	-26	-21	-21	N/A
12/31/2022	2	-24	-18	-18	N/A
9/30/2022	N/A	-21	-15	-15	N/A
6/30/2022	N/A	-17	-12	-12	N/A
3/31/2022	N/A	-16	-13	-13	N/A
12/31/2021	N/A	-17	-14	-14	N/A
9/30/2021	0	-16	-14	-14	N/A
6/30/2021	0	-18	-17	-17	N/A
3/31/2021	0	-19	-15	-15	N/A
12/31/2020	0	-18	-16	-16	N/A
9/30/2020	N/A	-18	-14	-14	N/A
6/30/2020	N/A	-14	-11	-11	N/A
3/31/2020	N/A	-14	-10	-10	N/A
12/31/2019	N/A	-13	-9	-9	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-13	-10	-10	N/A
3/31/2019	N/A	-11	-9	-9	N/A
12/31/2018	N/A	-10	-8	-8	N/A
9/30/2018	N/A	-9	-6	-6	N/A
6/30/2018	N/A	-9	N/A	-6	N/A
3/31/2018	N/A	-8	N/A	-5	N/A
12/31/2017	N/A	-7	N/A	-4	N/A
9/30/2017	N/A	-6	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-3	N/A
3/31/2017	N/A	-3	N/A	-2	N/A
12/31/2016	N/A	-3	N/A	-2	N/A
9/30/2016	N/A	-2	N/A	-2	N/A
6/30/2016	N/A	-2	N/A	-2	N/A
3/31/2016	N/A	-1	N/A	-2	N/A
12/31/2015	N/A	-1	N/A	-2	N/A
9/30/2015	N/A	1	N/A	-2	N/A
6/30/2015	N/A	2	N/A	-2	N/A
3/31/2015	N/A	1	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-2	N/A
9/30/2014	N/A	-2	N/A	-2	N/A
6/30/2014	N/A	-5	N/A	-2	N/A
3/31/2014	N/A	3	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que FENC sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que FENC sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que FENC sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (27.9% al año) de FENC crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (27.9% al año) de FENC crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de FENC se prevé que sea elevada dentro de 3 años.

Fennec Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.9% to US$15.50

Consensus revenue estimates fall by 14%

Consensus EPS estimates increase by 18%

Price target increased by 11% to US$18.17

Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Fennec Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Fennec Pharmaceuticals Inc. Announces Management Appointments

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Price target decreased by 7.9% to US$15.50

Consensus revenue estimates fall by 14%

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Fennec Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 13, 2024

Consensus EPS estimates increase by 18%

Fennec Pharmaceuticals Inc. Announces CEO Changes

New minor risk - Share price stability

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Fennec Pharmaceuticals Inc. Announces Executive Changes

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Chief Operating Officer recently sold US$414k worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Chief Operating Officer recently sold US$228k worth of stock

Fennec Pharmaceuticals Inc., Annual General Meeting, Jun 25, 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$18.17

Chief Financial Officer notifies of intention to sell stock

Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Fennec Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Issues Reminder of Non-Substitution of PEDMARK®? (Sodium Thiosulfate Injection) for Pediatric Patients Receiving Cisplatin

Chief Financial Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Independent Chairman of the Board exercised options to buy US$1.8m worth of stock.

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

CEO & Director recently bought US$119k worth of stock

Fennec Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 06, 2023

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Fennec Pharmaceuticals Inc. Announces the Appointment of Adrian Haigh as Chief Operating Officer

Fennec Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently sold US$42k worth of stock

Chief Financial Officer notifies of intention to sell stock

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™? (sodium Thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Consensus revenue estimates increase by 10%, EPS downgraded

Fennec Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Fennec Pharmaceuticals Inc. Announces Pedmark® (Sodium Thiosulfate Injection) Receives Orphan Drug Exclusivity from U.S. FDA

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

CEO & Director recently sold US$276k worth of stock

Insufficient new directors

Insufficient new directors

Fennec Pharmaceuticals Inc. Announces Commercial Availability of PEDMARK(R) (Sodium Thiosulfate Injection) in the United States

Insufficient new directors

Berkshire Sterile Client Fennec Pharmaceuticals Inc. Receives FDA Approval on Product Indicated to Reduce Risk of Hearing Loss for Childhood Cancer Patients

Price target increased to US$12.00

Fennec Pharmaceuticals Inc. Announces FDA Approval of PEDMARK

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

CEO & Director exercised options to buy US$350k worth of stock.

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Fennec Pharmaceuticals Inc. announced that it expects to receive $45 million in funding from Petrichor Healthcare Capital Management LP

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Fennec Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2022

The Law Offices of Vincent Wong Remind Fennec Pharmaceuticals Inc. Investors of A Lead Plaintiff Deadline of April 11, 2022

Pomerantz Law Firm Files Class Action Against Fennec Pharmaceuticals Inc. and Certain of Its Officers

Shubh Goel to Depart Fennec Pharmaceuticals Inc. as Chief Commercial Officer in Late February 2022

Price target decreased to US$10.80

Consensus revenue estimates increase to US$25.0m

Forecast breakeven date moved forward to 2021

Fennec Pharmaceuticals Inc. Expects to Receive Complete Response Letter from the FDA for Its New Drug Application for Pedmark

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Forecast breakeven moved forward to 2021

Elion Oncology, Inc. acquired Eniluracil from Fennec Pharmaceuticals, Inc. for $0.04 million.

Fennec Could See Upside If Pedmark Gets Approved

Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 3000 Growth Index

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™